Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Psychedelic Treatments

News
Delix Receives NIDA Grant to Advance Neuroplastogen for SUD
12/19/2023
Tom Valentino, Digital Managing Editor
Delix Therapeutics has been awarded a $320,000 grant from the National Institute on Drug Abuse to support the advancement of its novel neuroplastogen and non-hallucinogenic ibogaine analog, DLX-007.
Delix Therapeutics has been awarded a $320,000 grant from the National Institute on Drug Abuse to support the advancement of its novel neuroplastogen and non-hallucinogenic ibogaine analog, DLX-007.
Delix Therapeutics has been...
12/19/2023
Behavioral Healthcare Executive
News
Psilocybin Improves Recovery Rate Among AUD Patients
08/31/2022
Tom Valentino, Digital Managing Editor
When combined with psychotherapy, 2 doses of psilocybin reduced drinking by an average of 83% among heavy drinkers, according to a new study led by researchers at NYU Grossman School of Medicine.
When combined with psychotherapy, 2 doses of psilocybin reduced drinking by an average of 83% among heavy drinkers, according to a new study led by researchers at NYU Grossman School of Medicine.
When combined with...
08/31/2022
Psych Congress Network
News
Researchers Receive NIDA Grant to Study Nonhallucinogenic Compounds to Treat SUD
05/27/2022
Tom Valentino, Digital Managing Editor
Researchers from the University of California, Davis, and the University of Colorado Anschutz Medical Campus will screen hundreds of compounds.
Researchers from the University of California, Davis, and the University of Colorado Anschutz Medical Campus will screen hundreds of compounds.
Researchers from the University...
05/27/2022
Psych Congress Network
News
Researchers to Study Use of Ibogaine to Treat Methadone Withdrawal Symptoms
05/20/2022
Tom Valentino, Digital Managing Editor
ICEERS has partnered with Sant Joan de Reus University Hospital to conduct a clinical trial of a novel ibogaine treatment protocol to support patients tapering off methadone.
ICEERS has partnered with Sant Joan de Reus University Hospital to conduct a clinical trial of a novel ibogaine treatment protocol to support patients tapering off methadone.
ICEERS has partnered with Sant...
05/20/2022
Psych Congress Network
Timothy Ko, CEO, Entheon Biomedical
Perspectives
Can Psychedelic-Assisted Therapies Be a New Solution For Addiction Problems?
02/22/2022
Timothy Ko
Psychedelic-assisted therapy, and specifically DMT, shows promise in improving the odds of individuals seeking to recover from addiction disorders.
Psychedelic-assisted therapy, and specifically DMT, shows promise in improving the odds of individuals seeking to recover from addiction disorders.
Psychedelic-assisted therapy,...
02/22/2022
Addiction Professional
News
University of Wyoming, CaaMTech to Study Potential of Psychedelic Compounds to Treat Addiction
12/16/2021
Tom Valentino, Digital Managing Editor
The University of Wyoming School of Pharmacy announced that it has formed a collaboration with CaaMTech, a Washington state-based developer of psychedelic drugs, to evaluate the company’s proprietary compounds as treatments for addiction.
The University of Wyoming School of Pharmacy announced that it has formed a collaboration with CaaMTech, a Washington state-based developer of psychedelic drugs, to evaluate the company’s proprietary compounds as treatments for addiction.
The University of Wyoming School...
12/16/2021
Addiction Professional
News
Delix Partners With NIDA to Study Ibogaine Analog to Treat Multiple SUDs
12/09/2021
Tom Valentino, Digital Managing Editor
Delix Therapeutics has partnered with the National Institute on Drug Abuse to study the use of its DLX-7 ibogaine analog to treat multiple substance use disorders.
Delix Therapeutics has partnered with the National Institute on Drug Abuse to study the use of its DLX-7 ibogaine analog to treat multiple substance use disorders.
Delix Therapeutics has partnered...
12/09/2021
Psych Congress Network
News
NIH Awards First Grant for Psychedelic Treatment Research in 50 Years
10/27/2021
Tom Valentino, Senior Editor
Johns Hopkins Medicine has been awarded a grant by the National Institutes of Health to study the impacts of psilocybin on tobacco addiction. It is the first time in 50 years NIH funding has been awarded to directly investigate therapeutic...
Johns Hopkins Medicine has been awarded a grant by the National Institutes of Health to study the impacts of psilocybin on tobacco addiction. It is the first time in 50 years NIH funding has been awarded to directly investigate therapeutic...
Johns Hopkins Medicine has been...
10/27/2021
Psych Congress Network
News
DemeRx Begins Dosing Subjects in Study of Ibogaine for OUD
09/24/2021
Tom Valentino, Senior Editor
DemeRx, a Miami-based atai Life Sciences platform company that is developing ibogaine for the treatment of opioid use disorder, announced that the first subjects have been dosed in its Phase 1/2a clinical trial of ibogaine HCl (DMX-1002), an...
DemeRx, a Miami-based atai Life Sciences platform company that is developing ibogaine for the treatment of opioid use disorder, announced that the first subjects have been dosed in its Phase 1/2a clinical trial of ibogaine HCl (DMX-1002), an...
DemeRx, a Miami-based atai Life...
09/24/2021
Psych Congress Network
News
Reliance on Substances, Vices as Coping Mechanisms Climbs During Pandemic
05/20/2021
More than 80% of Americans have reported showing signs of depression during the COVID-19 pandemic, more than a quarter have either contemplated or engaged in serious self-harm, and many are using illicit substances and vices to cope with...
More than 80% of Americans have reported showing signs of depression during the COVID-19 pandemic, more than a quarter have either contemplated or engaged in serious self-harm, and many are using illicit substances and vices to cope with...
More than 80% of Americans have...
05/20/2021
Addiction Professional

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement